Methods for diagnosis, prognosis and methods of treatment

A method of drug screening, said method comprising:

• classifying one or more hematopoietic cells associated with acute leukemia, myelodysplastic syndrome or myeloproliferative neoplasms in said individual by a method comprising:
• a) subjecting a cell population comprising said one or more hematopoietic cells from said individual to a test compound and a plurality of modulators in separate cultures, wherein:
• i) a first modulator is a growth factor or a mitogen,
• ii) a second modulator is a cytokine,
• iii) a third modulator is a modulator that slows or stops the growth of cells, and/or induces apoptosis of cells, and/or is an inhibitor of a cellular function,
• b) determining an activation level of at least one activatable element in one or more cells from each of said separate cultures, wherein the at least one activatable element is within the PI3K/AKT or MAPK pathways and the activation level is measured in response to said growth factor or mitogen, and
• c) classifying said one or more hematopoietic cells into groups comprising response or non-response to therapeutic treatment, or risk or relapse, based on said activation level of said at least one activatable element, said classification enabling a decision regarding the test compound and its therapeutic potential to treat acute leukemia, myelodysplastic syndrome or myeloproliferative neoplasms in said individual based on said classification of said one or more hematopoietic cells.